Extracorporeal circulation with danaparoid sodium for valve replacement in thrombocytopenia induced by type II heparin

A type II heparin-induced thrombocytopenia (HIT) was diagnosed in a 64-year-old woman at day 20 of intravenous unfractionated heparin (UFH) therapy, given after myocardial infarction treated by angioplasty and intracoronary stent. The infarction was complicated by a mitral insufficiency that led to...

Full description

Saved in:
Bibliographic Details
Published in:Annales françaises d'anesthésie et de réanimation 2001-11, Vol.20 (9), p.799
Main Authors: Salmi, L, Leroy-Matheron, C, LeBesnerais, P, Rosanval, O, Duvaldestin, P, Gouault-Heilmann, M
Format: Article
Language:fre
Subjects:
Anticoagulants - therapeutic use
Chondroitin Sulfates - therapeutic use
Dermatan Sulfate - therapeutic use
Drug Combinations
Extracorporeal Circulation
Female
Heart Valve Prosthesis
Heparin - adverse effects
Heparitin Sulfate - therapeutic use
Humans
Middle Aged
Mitral Valve Insufficiency - complications
Mitral Valve Insufficiency - surgery
Thrombocytopenia - chemically induced
Thrombocytopenia - complications
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A type II heparin-induced thrombocytopenia (HIT) was diagnosed in a 64-year-old woman at day 20 of intravenous unfractionated heparin (UFH) therapy, given after myocardial infarction treated by angioplasty and intracoronary stent. The infarction was complicated by a mitral insufficiency that led to a mitral valve replacement. Cardiopulmonary bypass was successfully performed with sodium danaparoid (Orgaran), as an alternative to UFH, without thrombotic or haemorrhagic complications and the follow-up was uneventful.
ISSN:0750-7658